Berns on Nephrology

 
 
  • Postpone Dialysis Until Symptoms Occur   Dr. Jeffrey Berns reviews new guidelines from the Canadian Society of Nephrology that encourage clinicians to wait for patient symptoms before starting dialysis
  • Paying for Kidneys: A Good Idea?   Dr. Jeffrey Berns reflects on recent articles that discuss the merits and pitfalls of offering cash to potential kidney donors.
  • Renal Denervation, R.I.P.?   Dr. Jeffrey Berns discusses the implications of halting SYMPLICITY HTN-3, a study that was testing catheter-based renal denervation for the treatment of resistant hypertension.
  • Mortality Rates at Dialysis Centers: What Matters?   Dr. Jeffrey Berns reviews a study that compares mortality rates at for-profit dialysis facilities vs at nonprofit ones, reminding physicians that they are ultimately responsible for patients' care
  • What Does 'No Evidence' Really Mean?   What should clinicians do when 'there is no evidence to suggest' a certain treatment path? Dr. Jeffrey Berns reflects on a recent column in JAMA.
  • ACE + ARB = Adverse Events   If you have any patients on both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker, you probably should discontinue one of those medications, says Dr. Jeffrey Berns.
  • The Future of Nephrology   'We need to be truly expert' in managing chronic kidney disease, says Dr. Jeffrey Berns, in order to preserve the specialty of nephrology.
  • Don't Stop Looking for CKD!   Dr. Jeffrey Berns explains why recent guidelines discouraging kidney screening have been so controversial in the nephrology community.
  • Remembering the Gratifying Moments in Nephrology   Dr. Jeffrey Berns shares some highlights from his practice as a reminder to appreciate the positive aspects of being a nephrologist.
  • The Vulnerable Kidney: Any Protection During Surgery?   Jeffrey Berns discusses a recent Cochrane review on studies that showed no evidence that any options worked in protecting renal function during surgery.
  • The Looming Specter of Chronic Kidney Disease   Jeffrey Berns talks about a recent analysis that predicts a troubling prevalence of chronic kidney disease in the United States, with a nearly 60% risk of developing stage 3a CKD.
  • Dialysis Case Load: Less Is More   Jeffrey Berns talks about a new study that found higher mortality rates with high case loads.
  • Future Nephrologist: Hospital-Based and Tied to Dialysis?   Dr. Jeffrey Berns offers a sobering view of the future of nephrology and foresees the specialty being limited to the hospital and to the dialysis patient.
  • Big Payment Reductions Looming in Dialysis; Others Beware   Jeffrey Berns discusses CMS announcements on bundle payments that will have negative effects for dialysis providers.
  • Meaningful Use: Avoiding Looming Penalties   Jeffrey Berns talks about meaningful use and what you need to know to avoid the looming penalties
  • IV Iron in CKD: Understanding the Guidelines   Dr. Jeffrey Berns provides perspective on sections in the KDIGO guidelines on managing chronic kidney disease that deal with intravenous iron.
  • Make Your Own Kidney: Step 1   Jeffrey Berns talks about a recent Nature study that reported on the bioengineering of rat kidneys in the lab.
  • Starting Dialysis; Does the Patient Have to Be Very Sick?   Jeffrey Berns discusses the KDIGO recommendations for starting dialysis and talks about his discomfort with waiting until patients are very sick.
  • Understanding Meds for CKD Patients   Jeffrey Berns talks about medication safety in patients and the importance of communicating to nonnephrologists the specific hazards in patients with kidney disease.
  • Sevelamer: A Phosphate Binder Friend With Benefits?   Jeffrey Berns discusses the phosphate binder sevelamer and suggests that anti-inflammatory or antioxidant effects might be an added benefit for patients with kidney disease.